



# Surgical Myectomy is the Best Treatment for Symptomatic Obstructive HCM (For Most Patients)

Ehud Raanani, M.D.

Jerusalem  
April 23, 2013




The Leviev Heart Center

# Outcome of Myectomy for HCM

## Mayo Clinic

- Operative mortality 0.8%
- Gradient reduction 67 → 3 mm Hg
- Postop NYHA 1-2 94%

# Myectomy for HCM Mayo Clinic 1973-2012



# Sheba MC Experience

- 77 pts with HOCM and MR underwent Septal Myectomy from 12/2004 till 12/2012.
- LVOT obstruction: Mean rest  $56 \pm 37$ mmHg and  $80 \pm 39$  mmHg in valsalva.
- Mean Age:  $61 \pm 15$  y
- Gender: 47 % M, 53% F
- Mean NYHA FC:  $2.4 \pm 0.8$

# Patients (CONT)


- Concomitant procedures

Any Procedure	45(60%)
AVR/AVre	27(35%)
MVR/MVr	15(19%)
CABG	12(16%)
Maze	8(10%)
Aorta	1(1%)


- Redo Operation : 8 (10%)

# Pre-operative MR


**Mean MR  $2.3 \pm 0.9$**




# Relationship between LVOT gradient and degree of MR (Pre Op.)




# Trans-aortic septal myectomy










# Early Results


- Mortality : 0 (0%)
- CVA : 0 (0%)
- Pacemaker : 8 (10%)
- Length of Stay :  $7 \pm 5$  days

# Late Echo




# Septal Scarring

Post-Ablation



Septal scar

Post-Myectomy




No scar

# Septal Myectomy versus Septal Infarction


## MRI Study

Surgical septal myectomy –  
34 patients




Resected tissue  
 $2.7 \pm 1.4\%$  of LV mass  
Range 0.8-5.9

Alcohol septal ablation –  
45 patients




Infarcted tissue  
 $8 \pm 3\%$  of LV mass  
Range 3.6-13.6

# Short-Term Mortality




# Post-Intervention Pacemaker Implantation






# Post-Procedure Mean NYHA



# Post-Procedure Left Ventricular Outflow Tract Gradient



# Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

Peter A. Noseworthy, MD<sup>a</sup>, Michael A. Rosenberg, MD<sup>b</sup>, Michael A. Fifer, MD<sup>a</sup>, Igor F. Palacios, MD<sup>a</sup>, Patricia A. Lowry, NP<sup>a</sup>, Jeremy N. Ruskin, MD<sup>c</sup>, Danita M. Sanborn, MD<sup>a</sup>, Michael H. Picard, MD<sup>a</sup>, Gus J. Vlahakes, MD<sup>d</sup>, Theofanie Mela, MD<sup>c</sup>, and Saumya Das, MD, PhD<sup>c,\*</sup>





Figure 2. Risk of VT, cardiac arrest, or appropriate ICD therapy increased as post-ASA gradient increased. Created using Lowness smoothing from Cox regression model incorporating post-ASA gradient.


# Residual LVOT Gradient After Septal Ablation and Survival Free of All-Cause Mortality



No. at risk

—	130	121	108	105	87	74	56	43	23
—	47	44	40	36	34	31	25	22	17

# Survival-Free of Death or Need for Additional Septal Reduction Therapy ; Septal Ablation in Comparison Matched Population of Surgical Myectomy



No. at risk

—	177	159	138	126	107	93	69	56	33
—	177	175	169	161	139	118	98	77	56

# Predictors of All-Cause Mortality

	<b>Univariate risk ratio</b>	<b>P</b>	<b>Multivariate risk ratio*</b>	<b>P</b>
Age (per year)	1.54 (1.51-1.57)	<0.0001	1.09 (1.03-1.15)	0.004
Male	1.82 (1.11-2.94)	0.01	0.51 (0.24-1.08)	0.07
Hypertension	1.54 (0.95-2.50)	0.07		
Atrial fibrillation	2.04 (1.15-3.70)	0.01		
CAD	1.96 (0.87-4.35)	0.09		
ESD (per mm increase)	1.09 (1.00-1.19)	0.03		
EDD (per mm increase)	1.06 (1.00-1.12)	0.03		
Postablation LVOT gradient (per 5 mm Hg increase)	1.10 (1.03-1.17)	0.002	1.04 (1.01-1.07)	0.004
β-blocker therapy	1.53 (0.92-2.52)	0.09		


\*Only age, male sex and postablation LVOT gradient included in final multivariate model

*Sorajja et al: Circ 126:2374, 2012*

# Univariate and Multivariate Predictors of Hemodynamic Success

	Univariate			Multivariate		
	RR	95% CI	P	RR	95% CI	P
Age	1.84	0.91-3.72	0.08	1.03	1.00-1.07	0.02
LVOT gradient						
Resting	0.96	0.95-0.98	<0.0001	0.96	0.94-0.97	<0.0001
Provocable	0.97	0.95-0.99	0.002	—		
Septal thickness						
Maximal	0.93	0.86-0.99	0.03	—		
1 cm proximal to SAM	0.83	0.74-0.92	0.003	—		
At SAM-septal contact	0.87	0.79-0.95	0.002	0.85	0.75-0.96	0.009
C-septum distance	1.07	0.98-1.17	0.04	—		
LAD ref diam	0.62	0.41-0.94	0.02	0.96	0.94-0.97	0.05
Case no. <51	0.31	0.15-0.64	0.001	0.39	0.15-1.00	0.04

Hemodynamic success was defined as post-procedural resting gradient of <10 mm Hg and >80% reduction in provocable gradient



Favorable variables:


- age  $\geq 65$ y
- LVOT grad  $\leq 100$ mmhg
- LAD  $< 4.0$ mm
- Basal septum  $\leq 18$ mm
- Case no  $> 50$  patients




# Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy

## A Word of Caution

Folkert J. ten Cate, MD, PhD; Osama I.I. Soliman, MD, PhD; Michelle Michels, MD; Dominic A.M.J. Theuns, PhD; Peter L. de Jong, MD; Marcel L. Geleijnse, MD, PhD; Patrick W. Serruys, MD, PhD



# Septal Reduction – Mayo Clinic



# Septal Myectomy versus Septal Infarction

## Conclusions

- Low early mortality with either procedure
- More reliable relief of gradient with myectomy
- Less collateral myocardial injury
  - Fewer A-V conduction problems, young pt
  - Arrhythmias ?
- Fewer anatomic limitations
- Repair of associated problems

**Thank You!**

# **Outcome of Surgical Myectomy After Unsuccessful Alcohol Septal Ablation for the Treatment of Patients With Hypertrophic Obstructive Cardiomyopathy**

Sherif F. Nagueh, MD, FACC,\* John M. Buegler, MD, FACC,\* Miguel A. Quinones, MD, FACC,\* William H. Spencer III, MD, FACC,† Gerald M. Lawrie, MD, FACC\*

*Houston, Texas; and Charleston, South Carolina*

The medical records of 375 patients who underwent alcohol ablation at our institution were reviewed. Twenty patients (5.3%, mean age  $53 \pm 18$  years, 17 women) subsequently needed surgical myectomy. The New York Heart Association (NYHA) functional class, angina class, exercise duration, left ventricular outflow tract (LVOT) gradient, ejection fraction, and septal thickness were tabulated. The anatomy and distribution of the septal perforator arteries were examined.

Myectomy can be successfully performed after failed alcohol ablation, but with a higher incidence of heart block than in cases where only surgery is performed. Otherwise, alcohol ablation does not appear to adversely affect surgical outcome. (J Am Coll Cardiol 2007;50:795–8) © 2007 by the American College of Cardiology Foundation

## Advantages of Septal Myectomy


- Higher success rate
- Sustained 'immediate' relief of LVOT obstruction
- Long-term durability of benefit
- Lower rate of PPM, fewer late arrhythmias?
- Address other obstruction or lesions

## Advantages of Alcohol Septal Ablation

- Patient satisfaction 
  - Pain
  - Recovery time
- Impact of older age and comorbidities on surgical risk
- Lower cost


# The Ablation Scar

Post-Ablation




Septal scar

Post-Myectomy



No scar



**Figure 5**





**CMR Image After Septal Myectomy Versus Septal Ablation**

**Top panels** show long-axis cardiovascular magnetic resonance (CMR) imaging views before (**left**) and after (**right**) septal myectomy. The portion of basal septum evident in this plane, projecting into the left ventricular (LV) outflow tract, has been resected at myectomy (**arrows**). **Bottom panels** show long-axis views before (**left**) and 5 months after (**right**) septal ablation. The ablation has spared the most proximal portion of basal septum at the level of systolic anterior motion and mitral valve-septal contact, involving only the more distal septum below this level of obstruction (**arrows**). AML = anterior mitral leaflets; Ao = aorta; LA = left atrium; RV = right ventricle.





# Case Presentation



## Pre op TTE



# 57 y/o male with HCM

## No Subaortic Obstruction







# Relationship between LVOT gradient and degree of MR (Pre Op.)

MR grade	Rest	P value	Valsalva	P value
MR grade 0/1 Trivial	40±28	0.567	54±24	0.015
MR grade 2 Mild	55± 44		71±34	
MR grade 3 Moderate	64±37		105±46	
MR grade 4 Severe	66±17		113±20	

# Late Results

- FU Duration :  $26 \pm 23$  months, 100% complete.
- Mean NYHA FC:  $1.9 \pm 0.8$ .
- Late Deaths : 4
  - 3 non-cardiac
  - 1 cardiac
- Total Major Complications : 8 (10%)
  - Arrhythmia : 8 (10%)
  - CVA : 4 (5%)
  - MI : 0(0%)
  - TIA : 0(0%)
  - Pacemaker : 0(0%)

# Relationship Between Residual LVOT Gradient and Degree of MR

MR grade	Rest	P value	Valsalva	P value
MR grade 0-1 Trivial	12 ±5	0.257	21 ± 30	0.340
MR grade 2-4 Mild - severe	2 ± 3		3 ± 6	

# Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

## Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment

Robert A. Leonardi, MD; Evan P. Kransdorf, MD, PhD;  
David L. Simel, MD, MHS; Andrew Wang, MD

**Background**—Septal reduction for obstructive hypertrophic cardiomyopathy may be performed by surgical myectomy or alcohol septal ablation (ASA). Unlike surgical myectomy, ASA creates an intramyocardial scar that may potentiate the risk of ventricular arrhythmias and sudden cardiac death (SCD).


**Methods and Results**—Systematic reviews for ASA and surgical myectomy were performed. Study selection and data extraction were completed independently by 2 investigators. Comparative data analyses were completed using a random effects model and regression analysis. Kappa statistics for agreement on initial study inclusion were high for both ASA (0.78; 95% CI, 0.68 to 0.88) and surgical myectomy studies (0.95; 95% CI, 0.84 to 1.0). Nineteen ASA studies (2207 patients) and 8 surgical myectomy studies (1887 patients) were included. Median follow-up was shorter for ASA than for myectomy studies (51 versus 1266 patient-years;  $P < 0.001$ ). For ASA and surgical myectomy, unadjusted rates (events/patient-years) of all-cause mortality (0.021 versus 0.018, respectively;  $P = 0.37$ ) and SCD (0.004 versus 0.003, respectively;  $P = 0.36$ ) were similar. Patients treated with ASA were older (weighted mean, 55 versus 44 years;  $P < 0.001$ ) and had less septal hypertrophy (weighted mean, 21 versus 23 mm;  $P < 0.001$ ) compared with those treated with myectomy. After adjustment for available baseline characteristics, odds ratios for treatment effect on all-cause mortality and SCD were 0.28 (95% CI, 0.16 to 0.46) and 0.32 (95% CI, 0.11 to 0.97), respectively, favoring ASA.

**Conclusions**—Rates of all-cause mortality and SCD after both ASA and surgical myectomy were similarly low. Adjusted for baseline characteristics, the odds ratios for treatment effect on all-cause mortality and SCD were lower in ASA cohorts compared with surgical myectomy cohorts. (*Circ Cardiovasc Interv.* 2010;3:97-104.)

**Key Words:** hypertrophic cardiomyopathy ■ septal ablation ■ myectomy ■ meta-analysis




# Survival-Free of All-Cause Mortality for Patients with Septal Ablation in Comparison with Age- and Sex-Matched Population of Patients Who Underwent Surgical Myectomy



No. at risk

—	177	167	148	140	121	105	81	66	40
—	177	175	169	161	139	118	97	77	57

# Case Volume and Clinical Outcome



# Survival-Free of Severe Symptoms in Overall Population (linearly related to hemodynamic success)

